VYNE Therapeutics Inc.

NASDAQ: VYNE · Real-Time Price · USD
1.05
0.05 (5.00%)
At close: May 23, 2025, 3:59 PM
1.06
1.31%
After-hours: May 23, 2025, 05:25 PM EDT

Company Description

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions.

The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis.

It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.

The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020.

VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

VYNE Therapeutics Inc.
VYNE Therapeutics Inc. logo
Country United States
IPO Date Jan 25, 2018
Industry Biotechnology
Sector Healthcare
Employees 13
CEO David T. Domzalski

Contact Details

Address:
520 U.S. Highway 22
Bridgewater, New Jersey
United States
Website https://www.vynetherapeutics.com

Stock Details

Ticker Symbol VYNE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001566044
CUSIP Number 92941V209
ISIN Number US92941V3087
Employer ID 45-3757789
SIC Code 2834

Key Executives

Name Position
David T. Domzalski Chief Executive Officer, President & Director
Mutya Harsch J.D. General Counsel, Chief Legal Officer & Company Secretary
Tyler Zeronda CPA Chief Financial Officer & Treasurer
Dr. Darrell S. Rigel FAAD, M.D. Consultant
Dr. Iain A. Stuart Ph.D. Chief Scientific Officer

Latest SEC Filings

Date Type Title
May 19, 2025 SCHEDULE 13G/A [Amend] Filing
May 15, 2025 SCHEDULE 13G/A [Amend] Filing
May 15, 2025 SCHEDULE 13G/A [Amend] Filing
May 08, 2025 10-Q Quarterly Report
May 08, 2025 8-K Current Report
Apr 02, 2025 4 Filing
Apr 02, 2025 4 Filing
Apr 02, 2025 4 Filing
Apr 02, 2025 4 Filing
Mar 06, 2025 10-K Annual Report